Publicacións nas que colabora con José Ramón González Juanatey (95)

2024

  1. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  2. Manual de procedementos en pacientes críticos cardiovasculares

    Conselleria de Sanidade

  3. Videolaryngoscope versus conventional technique for insertion of a transesophageal echocardiography probe in intubated ICU patients (VIDLARECO trial): A randomized clinical trial

    Anaesthesia Critical Care and Pain Medicine, Vol. 43, Núm. 2

2023

  1. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 3055-3066

  2. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  3. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  4. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  2. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

  3. The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure

    Cells, Vol. 11, Núm. 8

  4. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. A New Biomarker Tool for Risk Stratification in “de novo” Acute Heart Failure (OROME)

    Frontiers in Physiology, Vol. 12

  3. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: Observational study using prospectively collected registry data

    BMJ, Vol. 375

  4. Long-term prognosis of women with Brugada syndrome and electrophysiological study

    Heart Rhythm, Vol. 18, Núm. 5, pp. 664-671

  5. Outcomes of Participants With Diabetes in the ISCHEMIA Trials

    Circulation, Vol. 144, Núm. 17, pp. 1380-1395

  6. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

  7. Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 23, Núm. 5, pp. 682-690

2020

  1. Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open-heart surgery

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 18, pp. 10958-10969

  2. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164